{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:37:14Z","timestamp":1790221034430,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T00:00:00Z","timestamp":1487548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T00:00:00Z","timestamp":1487548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1002\/jcph.880","type":"journal-article","created":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T11:46:44Z","timestamp":1487591204000},"page":"906-917","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial"],"prefix":"10.1002","volume":"57","author":[{"given":"Susan E.","family":"Shoaf","sequence":"first","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization; Rockville MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[{"name":"Division of Nephrology; Emory University School of Medicine; Atlanta GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension; Mayo Clinic; Rochester MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization; Rockville MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization; Rockville MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,20]]},"reference":[{"issue":"4","key":"10.1002\/jcph.880-BIB0001|jcph880-cit-0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1002\/jcph.880-BIB0002|jcph880-cit-0002","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1002\/jcph.880-BIB0003|jcph880-cit-0003","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/ndt\/15.8.1155","article-title":"Dissociation between urine osmolality and urinary excretion of aquaporin-2 in healthy volunteers","volume":"15","author":"Baumgarten","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1002\/jcph.880-BIB0004|jcph880-cit-0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"5","key":"10.1002\/jcph.880-BIB0005|jcph880-cit-0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"10.1002\/jcph.880-BIB0006|jcph880-cit-0006","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1002\/jcph.880-BIB0007|jcph880-cit-0007","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"issue":"7","key":"10.1002\/jcph.880-BIB0008|jcph880-cit-0008","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1002\/jcph.880-BIB0009|jcph880-cit-0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1002\/jcph.880-BIB0010|jcph880-cit-0010","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl(-) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"10.1002\/jcph.880-BIB0011|jcph880-cit-0011","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jcph.880-BIB0012|jcph880-cit-0012","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/jcem-38-2-278","article-title":"Radioimmunoassay measurement of arginine vasopressin in serum: development and application","volume":"38","author":"Skowsky","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1002\/jcph.880-BIB0013|jcph880-cit-0013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","article-title":"Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide","volume":"50","author":"Shoaf","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1002\/jcph.880-BIB0014|jcph880-cit-0014","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5414\/CP201621","article-title":"Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects","volume":"50","author":"Shoaf","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"10.1002\/jcph.880-BIB0015|jcph880-cit-0015","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00228-012-1295-5","article-title":"Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects","volume":"68","author":"Shoaf","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jcph.880-BIB0016|jcph880-cit-0016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1002\/jcph.880-BIB0017|jcph880-cit-0017","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0091270010376193","article-title":"In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects","volume":"51","author":"Shoaf","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1002\/jcph.880-BIB0018|jcph880-cit-0018","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/01.fjc.0000180899.24865.b6","article-title":"Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure","volume":"46","author":"Hauptman","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"10.1002\/jcph.880-BIB0019|jcph880-cit-0019","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1002\/jcph.880-BIB0020|jcph880-cit-0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1523-1755.1998.00990.x","article-title":"Regulation of cAMP production in initial and terminal inner medullary collecting ducts","volume":"54","author":"Yasuda","year":"1998","journal-title":"Kidney Int"},{"issue":"4","key":"10.1002\/jcph.880-BIB0021|jcph880-cit-0021","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/ki.2013.350","article-title":"Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function","volume":"85","author":"Shoaf","year":"2014","journal-title":"Kidney Int"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.880","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.880\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T12:43:13Z","timestamp":1658666593000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.880"}},"subtitle":["Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.880","archive":["Portico"],"relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2,20]]}}}